Chlamydia Infection Diagnostics Market - By Test Type (Nucleic Acid Amplification Test (NAAT), Serology Test, Direct Fluorescent Antibody Test, Culture Test), By Type of Infections (Genital Chlamydia Infection), By End-use (Hospitals), & Forecast, 2024 – 2032

Chlamydia Infection Diagnostics Market Size

Chlamydia Infection Diagnostics Market size was valued at USD 1.5 billion in 2023 and is anticipated to witness growth at a CAGR of 7.1% between 2024 and 2032, driven by technological advancements, increased awareness, and evolving healthcare needs.
 

Key trends include the rise in demand for rapid and accurate diagnostic tests, such as nucleic acid amplification testing and point-of-care (POC) tests, which offer high sensitivity and specificity for chlamydia trachomatis detection. The shift towards molecular diagnostics reflects the need for more precise and timely identification of infections, minimizing the risk of complications and transmission.
 

Additionally, there is a growing emphasis on home-based testing kits, driven by the increasing preference for convenience and privacy among patients. Innovations such as multiplex assays, which allow for the simultaneous detection of multiple sexually transmitted infections (STIs), are gaining traction due to their efficiency and cost-effectiveness. Public health initiatives and educational programs are also playing a crucial role in raising awareness and encouraging regular screening, contributing to the market's growth.
 

Furthermore, government initiatives are also anticipated to contribute to the growth of the market. For example, in June 2021, the U.K. government announced that the National Chlamydia Screening Programme (NCSP) would concentrate testing efforts on women, who face the greatest risk of severe outcomes from the infection. This initiative aims to expedite treatment and broaden testing in community settings for sexually active women under 25 years old. Such efforts by various governments to reduce disease burden are driving market expansion.
 

Chlamydia infection diagnostics refers to the methods and technologies used to detect and identify chlamydia trachomatis, a common sexually transmitted bacterium. Accurate diagnosis is crucial for effective treatment and prevention of complications associated with chlamydial infections. Diagnostic approaches typically include molecular tests like nucleic acid amplification tests (NAATs), which detect the genetic material of the bacterium with high sensitivity and specificity.
 

Other methods include enzyme immunoassays (EIAs) and direct fluorescence assays (DFAs), which identify bacterial antigens or antibodies produced in response to the infection. Point-of-care (POC) tests and home-based testing kits are becoming increasingly popular due to their convenience and rapid results. Early and accurate diagnosis is essential to manage the infection effectively, prevent transmission, and reduce the risk of long-term health issues, such as pelvic inflammatory disease, female infertility and male infertility.
 

Chlamydia Infection Diagnostics Market Trends

The rising prevalence of chlamydia infections is a significant driver for the growth of the market.
 

• Chlamydia trachomatis, a leading cause of sexually transmitted infections (STIs), has seen a marked increase in incidence globally, driven by factors such as changing sexual behaviours, increased rates of unprotected sex, and limited access to preventive healthcare. For instance, in 2021, the CDC reported a total of 1,628,379 cases of chlamydia trachomatis infection, making it the most frequently reported notifiable condition in the U.S. that year. This translates to a rate of 552.8 cases per 100,000 people, which represents a 2.8% increase from previous years.
   
• Additionally, according to the World Health Organization (WHO), chlamydia is one of the most frequently reported STIs, with millions of new cases annually, particularly affecting younger populations and those in high-risk groups. This growing prevalence underscores the urgent need for effective diagnostic tools to facilitate early detection and treatment.
   

• As the number of reported cases continues to rise, healthcare systems and public health authorities are prioritizing enhanced screening and diagnostic efforts. This focus is leading to a greater demand for advanced diagnostic solutions that offer high accuracy and rapid results. Molecular diagnostic techniques, such as nucleic acid amplification tests (NAATs), are increasingly favoured due to their superior sensitivity and specificity in detecting chlamydia trachomatis DNA. These tests can identify infections even in asymptomatic individuals, who are at risk of unknowingly transmitting the infection and suffering from long-term health complications if left untreated.
   
• Furthermore, the increased prevalence of chlamydia has heightened awareness and education around STI testing, driving more individuals to seek diagnostic services. The expansion of sexual health initiatives and campaigns that promote regular screening and early detection is also contributing to market growth. The availability of point-of-care (POC) tests and home-based testing kits has further amplified this trend, providing users with convenient and discreet options for testing, thus improving overall testing rates and accessibility.
   
• Healthcare providers are responding to this rising prevalence by investing in new diagnostic technologies and expanding testing programs, particularly in high-risk populations and underserved regions. Innovations such as multiplex assays, which can simultaneously detect multiple STIs, are becoming more prevalent, reflecting the need for comprehensive testing solutions.
   
• Additionally, the integration of digital health technologies and telemedicine is enhancing the reach of diagnostic services, enabling remote consultations and follow-up care, which aligns with the increased demand for efficient and accessible healthcare solutions.
   
• Overall, the escalating prevalence of chlamydia infections acts as a significant catalyst for the market, driving advancements in diagnostic technology, expanding testing infrastructure, and increasing the focus on effective infection management and prevention.
   

Chlamydia Infection Diagnostics Market Analysis

Based on test type the market is divided into nucleic acid amplification test (NAAT), serology test, direct fluorescent antibody test, culture test, and other test types. The nucleic acid amplification test (NAAT) segment dominated the market with a revenue of around USD 668.3 million in 2023.
 

• NAATs, which include polymerase chain reaction (PCR) and transcription-mediated amplification (TMA), have become the preferred diagnostic method due to their high sensitivity and specificity. NAATs can detect even low levels of Chlamydia trachomatis DNA, making them highly effective in identifying infections accurately. This precision reduces the likelihood of false negatives and ensures more reliable diagnoses compared to other methods.
   
• Many chlamydia infections are asymptomatic, especially in women. NAATs can identify these asymptomatic cases, which is crucial for early intervention and prevention of complications such as pelvic inflammatory disease and infertility.
   
• NAATs offer rapid results, often within hours, which is essential for timely diagnosis and treatment. This speed improves patient management and helps reduce the spread of infection.
   
• The advancement of digital health technologies has facilitated the integration of NAATs into point-of-care (POC) testing and home-based testing kits. This accessibility allows for widespread testing and easier monitoring of infection rates.
   

Based on type of infections the chlamydia infection diagnostics market is segmented into genital chlamydia infection, rectal chlamydia infection, and ocular chlamydia infection. The genital chlamydia infection segment dominated the market with a share of 67.4% in 2023.
 

• Genital chlamydia infections are the most common form of chlamydial infection, particularly affecting sexually active individuals. According to the Centers for Disease Control and Prevention (CDC), genital chlamydia is one of the most frequently reported STIs globally, contributing significantly to the market's focus on diagnosing this infection.
   
• There is heightened awareness and public health emphasis on sexually transmitted infections (STIs), including genital chlamydia. Initiatives aimed at increasing screening rates, particularly among high-risk populations such as young adults and those with multiple sexual partners, drive the demand for diagnostic tests.
   

Based on end-use the chlamydia infection diagnostics market is segmented into hospitals, specialty clinics, and diagnostic centres. The hospitals segment dominated the market in 2023 and is predicted to rise rapidly during the forecast period with a CAGR of 7.4%
 

• Hospitals are equipped with advanced diagnostic technologies and laboratories capable of performing a wide range of tests, including nucleic acid amplification tests (NAATs) and other molecular diagnostics. This extensive infrastructure allows hospitals to provide accurate and efficient chlamydia testing, driving their prominence in the market.
   
• Hospitals handle a significant volume of patients, including those presenting with symptoms of sexually transmitted infections (STIs) or undergoing routine screening. This high patient turnover necessitates robust diagnostic capabilities, positioning hospitals as major users of chlamydia infection diagnostics.
   
• Hospitals offer an integrated approach to patient care, including diagnosis, treatment, and follow-up services. The ability to provide comprehensive STI management within a single facility enhances patient convenience and ensures continuity of care, making hospitals a preferred setting for chlamydia testing.
   

North America chlamydia infection diagnostics market accounted for USD 588.1 million in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• North America, particularly the U.S., has one of the highest rates of chlamydia infections globally. This high prevalence drives the demand for effective diagnostic solutions to manage and control the spread of the infection.
   
• Public health organizations in North America, such as the Centers for Disease Control and Prevention (CDC), actively promote regular screening and early detection of chlamydia. Initiatives such as routine screening recommendations for sexually active individuals under 25 and targeted programs for high-risk populations contribute to increased demand for diagnostic tests.
   
• The adoption of advanced diagnostic technologies, including nucleic acid amplification tests (NAATs), has significantly improved the accuracy and speed of chlamydia testing. NAATs, known for their high sensitivity and specificity, are becoming increasingly popular in North America due to their ability to detect infections even in asymptomatic individuals.
   
• There is growing awareness and education about sexually transmitted infections (STIs) and their health impacts. Campaigns and educational programs that highlight the importance of STI testing and the availability of modern diagnostic tools are contributing to higher testing rates and market growth.
   

U.S. chlamydia infection diagnostics market accounted for USD 546.6 million market revenue in 2023 and is estimated to hold substantial share between 2024 to 2032.
 

• The rising number of product approvals is anticipated to fuel market growth in the country. For instance, in August 2021, Visby Medical obtained 510(k) clearance and a waiver under the Clinical Laboratory Improvement Amendments of 1988 from the U.S. Food and Drug Administration (FDA) to market its rapid PCR diagnostic test for the multiplexed detection of chlamydia.
   
• Likewise, in May 2022, Abbott received FDA clearance for its Alinity m STI assay, which can detect chlamydia using either a swab sample or a urine sample collected by a clinician or patient in a healthcare setting.
   

Germany chlamydia infection diagnostics market is projected to grow remarkably in the coming years.
 

• The rising prevalence of chlamydia infections is a key driver, with over 1.8 million cases reported annually in Europe, highlighting the need for effective diagnostics.
   
• Increasing awareness and routine screening initiatives are also contributing to market growth, as Germany has implemented various public health campaigns to promote sexual health.
   
• Additionally, technological advancements in diagnostic methods, such as PCR tests, offer faster and more accurate results, further boosting the market. The growing focus on early detection and treatment is also likely to enhance market expansion.
   

Japan holds a dominant position in the Asia Pacific chlamydia infection diagnostics market.
 

• The high prevalence of chlamydia infections, particularly among young adults, has increased demand for effective diagnostics. Japan reported over 30,000 cases of chlamydia in recent years, underscoring the need for improved detection.
   
• Additionally, the Japanese government has actively promoted sexual health awareness and routine screening programs, contributing to market growth.
   
• Technological advancements, such as the development of rapid and accurate PCR-based diagnostic tests, have further strengthened Japan's market presence. Moreover, collaborations between Japanese healthcare providers and diagnostic companies have enhanced accessibility to advanced testing solutions.
   

Chlamydia Infection Diagnostics Market Share

The market features a diverse range of companies. Leading corporations are focused on strengthening their market position through new product releases, mergers and acquisitions, and the adoption of cutting-edge technologies.
 

Chlamydia Infection Diagnostics Market Companies

Some of the eminent market participants operating in the chlamydia infection diagnostics industry include:

• Abbott
• BD
• Bio-Rad Laboratories, Inc.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• QuidelOrtho Corporation.
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Trinity Biotech Plc.
   

Chlamydia Infection Diagnostics Industry News:

• In January 2022, Roche announced the launch of the cobas pulse system in select countries after obtaining the CE Mark. The cobas pulse system is Roche Diagnostics' most innovative line of connected point-of-care solutions for professional blood glucose administration. The cobas pulse system, an industry first, combines the form factor of a high-performance blood glucose meter with simple usability and enhanced digital capabilities comparable to those of a smartphone.
   
• In November 2021, Roche announced the introduction of the cobas 5800 System, a revolutionary molecular laboratory instrument, in countries that have obtained the CE mark. Testing is one of the first lines of defense for a patient's overall well-being and is critical in quickly guiding their therapy. The cobas 5800 System helps laboratories address difficulties like increased patient testing, reimbursement complications, and the need for a more differentiated testing menu, all while providing relevant and timely results.
   

Chlamydia infection diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Nucleic acid amplification test (NAAT)
• Serology test
• Direct fluorescent antibody test
• Culture test
• Other test types

Market, By Type of Infections

• Genital chlamydia infection
• Rectal chlamydia infection
• Ocular chlamydia infection

Market, By End-use

• Hospitals
• Specialty clinics
• Diagnostic centres

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East & Africa